Medicines Development for Global Health   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Melbourne Australia (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2010
NCT01123915
First Marketed Drug
2018
moxidectin
First NDA Approval
2018
moxidectin
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

MDGH | Medicines Development for Global Health | Medicines Development Limited

Active Ingredients

Marketed Drugs (1)

moxidectin (2018 NDA)

Drugs in Phase 3 Trials (2)

ivermectin (stromectol) (2 trials)

moxidectin (6 trials)

Drugs in Phase 1 Trials (1)

opal-hiv-gag(c) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 1)

Infections (Phase 1)

Onchocerciasis (Phase 3)

Scabies (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3